Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Appointed director
Sage Therapeutics, Inc. (SAGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress"
06/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Bylaws of Sage Therapeutics, Inc"
05/02/2023 8-K Quarterly results
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression"
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation dated January 2023",
"Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference"
12/06/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
08/02/2022 8-K Quarterly results
Docs: "Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
07/14/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD"
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation dated January 2022",
"Corporate Presentation dated January 2022"
12/01/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD"
11/02/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress"
10/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022"
08/03/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress"
06/15/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
12/31/2020 8-K Quarterly results
12/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/27/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress"
10/15/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy